COVID-19 Response

COVID-19 Response

RedHill is committed to leveraging its research capabilities and proprietary assets to address the global health pandemic caused by the novel coronavirus (COVID-19). RedHill is working closely with regulatory authorities and the scientific community worldwide to evaluate the potential of its two investigational new drugs1, opaganib and RHB-107 to treat COVID-19 patients and support the global response to COVID-19. 

Opaganib (Yeliva, ACB294640) - a first-in-class, orally administered, sphingosine kinase-2 (SK2) selective inhibitor with a unique mechanism of action that has both anti-inflammatory and anti-viral activities.

RHB-107 (upamostat, WX-67) - a first-in-class, oral serine protease inhibitor active against a number of human trypsins and several other related serine proteases. Inhibition of serine proteases, including trypsins, may inhibit viral attachment and replication and decrease lung damage from viral pneumonia.

Learn more about our development programs for opaganib and RHB-107.

To find out more about RedHill Biopharma's Expanded Access policy, please visit:


1Opaganib and RHB-107 are investigational new drugs, not available for commercial distribution